Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M

Sight Sciences, Inc.

2025-Q2 EPS reported -$0.51 revenue$37,072,000

Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.
Surgical Glaucoma revenue $19.2M (-5% YoY); ordering accounts hit record 1,174, up 4%.
Dry Eye revenue fell to $0.3M from $1.1M as company focuses on reimbursed TearCare access.
Adjusted operating expenses $24.4M, down 8% YoY; reaffirmed FY25 guidance of $101-105M.
Tariff exposure on China products reduced from prior estimate of $3.5-4.5M to $1.0-1.5M for FY25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.